Pricing Log in Create free account

Immunome, Inc. (IMNM) vs Zymeworks Inc. (ZYME)

Immunome, Inc. and Zymeworks Inc. are both Biotechnology companies. Immunome, Inc. and Zymeworks Inc. are of similar size ($2.1B and $2.0B). Immunome, Inc. grew revenue faster over the last twelve months: 16.7% against −69.8%. Immunome, Inc. has the higher net margin (0.00% vs −404.0%) and the lower return on invested capital (−3,323.0% vs 0.00%). Across the 16 metrics below, Immunome, Inc. leads on 9 and Zymeworks Inc. on 7.

Valuation

Metric IMNM ZYME Biotechnology median
P/E n/m n/m 10.26
P/S 162.50 56.80 9.18
P/B 3.90 26.24 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales 121.23 49.52 8.98
Earnings yield (14.01%) (6.99%) (34.89%)
Free cash flow yield (10.71%) (5.76%) (24.52%)

Profitability

Metric IMNM ZYME Biotechnology median
Gross margin 100.00% (246.66%) 65.16%
Operating margin 0.00% (418.99%) 0.00%
Net margin 0.00% (404.00%) 0.00%
Free cash flow margin 0.00% (324.68%) 0.00%
Return on equity (64.03%) (72.31%) (50.12%)
Return on assets (59.03%) (37.25%) (45.60%)
Return on invested capital (3,322.99%) 0.00% 0.00%

Growth

Metric IMNM ZYME Biotechnology median
Revenue growth (TTM) 16.74% (69.78%) 6.26%
EPS growth (last fiscal year) 51.40% 33.33% 29.88%
Revenue growth, 5-year CAGR — 22.16% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IMNM ZYME Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 15.08 6.32 4.89
Net debt to EBITDA 2.92 2.81 1.01

Dividend

Metric IMNM ZYME Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric IMNM ZYME Biotechnology median
Market cap 2.11b 2.04b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack